Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial

George Sakoulas, Matthew Geriak, Ravina Kullar, Kristina L. Greenwood, MacKenzie Habib, Anuja Vyas, Mitra Ghafourian, Venkata Naga Kiran Dintyala, Fadi Haddad
doi: https://doi.org/10.1101/2020.07.20.20157891
George Sakoulas
1Sharp Memorial Hospital, 7910 Frost Street, San Diego, CA 92123
2Sharp Rees-Stealy Medical Group, 300 Fir Street, San Diego, CA 92101
3Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gsakoulas{at}health.ucsd.edu
Matthew Geriak
1Sharp Memorial Hospital, 7910 Frost Street, San Diego, CA 92123
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravina Kullar
4Expert Stewardship, Inc, 201 Ocean Avenue, Santa Monica, CA 90402
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristina L. Greenwood
5Sharp Center for Research, 8695 Spectrum Center Blvd, San Diego, CA 92123
PhD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MacKenzie Habib
5Sharp Center for Research, 8695 Spectrum Center Blvd, San Diego, CA 92123
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anuja Vyas
1Sharp Memorial Hospital, 7910 Frost Street, San Diego, CA 92123
2Sharp Rees-Stealy Medical Group, 300 Fir Street, San Diego, CA 92101
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitra Ghafourian
1Sharp Memorial Hospital, 7910 Frost Street, San Diego, CA 92123
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkata Naga Kiran Dintyala
1Sharp Memorial Hospital, 7910 Frost Street, San Diego, CA 92123
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fadi Haddad
6Sharp Grossmont Hospital, 5555 Grossmont Center Dr, La Mesa, CA 91942
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Interventions mitigating progression to mechanical ventilation in COVID-19 would markedly improve outcome and reduce healthcare utilization. We hypothesized that immunomodulation with IVIG would improve oxygenation and reduce length of hospital stay and progression to mechanical ventilation in COVID-19 pneumonia.

Methods Patients with COVID-19 were randomized 1:1 to prospectively receive standard of care (SOC) plus IVIG 0.5 g/kg/day × 3 days with methylprednisolone 40 mg 30 minutes before infusion versus SOC alone.

Results 16 subjects received IVIG plus SOC and 17 SOC alone. The median age was 51 years for SOC and 58 years for IVIG. APACHE II scores and Charlson comorbidity indices were similar for IVIG and SOC (median 7.5 vs 7 and 2 for both, respectively). Seven SOC versus 2 IVIG subjects required mechanical ventilation (p=0.12, Fisher exact test). Among subjects with A-a gradient of >200 mm Hg at enrollment, the IVIG group showed i) a lower rate of progression to requiring mechanical ventilation (2/14 vs 7/12, p=0.038 Fisher exact test), ii) shorter median hospital length of stay (11 vs 19 days, p=0.01 Mann Whitney U), iii) shorter median ICU stay (2.5 vs 12.5 days, p=0.006 Mann Whitey U), and iv) greater improvement in PaO2/FiO2 at 7 days (median [range] change from time of enrollment +131 [+35 to +330] vs +44·5 [-115 to +157], p=0.01, Mann Whitney-U test) than SOC.

Conclusion This pilot prospective randomized study comprising largely of Latino patients showed that IVIG significantly improved hypoxia and reduced hospital length of stay and progression to mechanical ventilation in COVID-19 patients with A-a gradient >200 mm Hg.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04411667

Funding Statement

Octapharma UCA, Inc. supported this work by providing IVIG (Octagam 10%). Octapharma USA, Inc. had no role in the design, analysis, or writing of the data presented.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Sharp Healthcare IRB reviewed and approved the above research protocol.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of Interest: None

  • Funding: IVIG (Octagam 10%) was provided by Octapharma USA, Hoboken, NJ

Data Availability

Data is currently under peer review. Crude data is available without patient identifying information..

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 25, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial
George Sakoulas, Matthew Geriak, Ravina Kullar, Kristina L. Greenwood, MacKenzie Habib, Anuja Vyas, Mitra Ghafourian, Venkata Naga Kiran Dintyala, Fadi Haddad
medRxiv 2020.07.20.20157891; doi: https://doi.org/10.1101/2020.07.20.20157891
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial
George Sakoulas, Matthew Geriak, Ravina Kullar, Kristina L. Greenwood, MacKenzie Habib, Anuja Vyas, Mitra Ghafourian, Venkata Naga Kiran Dintyala, Fadi Haddad
medRxiv 2020.07.20.20157891; doi: https://doi.org/10.1101/2020.07.20.20157891

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (433)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3307)
  • Dentistry and Oral Medicine (365)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1174)
  • Epidemiology (13391)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5167)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3281)
  • Health Policy (1144)
  • Health Systems and Quality Improvement (1196)
  • Hematology (432)
  • HIV/AIDS (1021)
  • Infectious Diseases (except HIV/AIDS) (14647)
  • Intensive Care and Critical Care Medicine (914)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4941)
  • Nursing (262)
  • Nutrition (733)
  • Obstetrics and Gynecology (887)
  • Occupational and Environmental Health (796)
  • Oncology (2526)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (546)
  • Pediatrics (1303)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4221)
  • Public and Global Health (7522)
  • Radiology and Imaging (1710)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (499)
  • Sports Medicine (425)
  • Surgery (550)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (206)